SKLB-677, an FLT3 and Wnt/[beta]-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML

• Published in: Scientific reports Vol. 5; p. 15646
• Main Authors: Ma, Shuang, Yang, Ling-ling, Niu, Ting, Cheng, Chuan, Zhong, Lei, Zheng, Ming-wu, Xiong, Yu, Li, Lin-li, Xiang, Rong, Chen, Li-juan, Zhou, Qiao, Wei, Yu-quan, Yang, Sheng-yong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 01.10.2015
• Subjects: Acute myeloid leukemia; Animal models; Clinical trials; Drug resistance; Leukemia; Myeloid leukemia; Stem cell transplantation; Stem cells; Wnt protein; β-catenin
• ISSN: 2045-2322
• DOI: 10.1038/srep15646

FLT3 has been identified as a valid target for the treatment of acute myeloid leukemia (AML), and some FLT3 inhibitors have shown very good efficacy in treating AML in clinical trials. Nevertheless, recent studies indicated that relapse and drug resistance are still difficult to avoid, and leukemia stem cells (LSCs) are considered one of the most important contributors. Here, we report the characterization of SKLB-677, a new FLT3 inhibitor developed by us recently. SKLB-677 exhibits low nanomolar potency in biochemical and cellular assays. It is efficacious in animal models at doses as low as 1mg/kg when administrated orally once daily. In particular, SKLB-677 but not first-generation and second-generation FLT3 inhibitors in clinical trials has the ability to inhibit Wnt/β-catenin signaling; Wnt/β-catenin signaling is required for the development of LSCs, but not necessary for the development of adult hematopoietic stem cells (HSCs). This compound indeed showed considerable suppression effects on leukemia stem-like cells in in vitro functional assays, but had no influence on normal HSCs. Collectively, SKLB-677 is an interesting lead compound for the treatment of AML, and deserves further investigations.